Immunicum announces that a patent application in China regarding the Company's CD70-technology will be granted

Gothenburg, Sweden, July 26, 2016. Immunicum AB (publ), a biopharmaceutical company pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced that the Chinese Patent Office (SIPO) intends to grant a patent relating to the Company's CD70-technology.

- We are pleased with the positive news from the Chinese Patent Office, SIPO, which gives us important protection for our CD70-technology, says Jamal El-Mosleh, CEO of Immunicum.

The Chinese patent to be granted, with the titel "Method for proliferation of antigen-specific T cells", protects the method for expansion of tumor specific T cells for so called adoptive immunotherapy with CAR T cells.

For further information, please contact:

Jamal El-Mosleh, CEO, Immunicum
Phone: +46 (0) 31 41 50 52
jamal.el-mosleh@immunicum.com

The Company's Certified Adviser is Redeye AB
Phone: +46 (0) 8 545 013 31. www.redeye.se

About Immunicum AB (publ)

Immunicum AB (publ) develops cancer immune primers for the treatment of tumor diseases. A phase II clinical trial for the Company's most advanced product - INTUVAX® against kidney cancer - has been initiated. The project portfolio contains additional clinical phase I/II studies in liver cancer and in gastrointestinal stromal tumors (GIST).
www.immunicum.com